scholarly journals High intensity focused ultrasound enhances anti-tumor immunity through promoting CD4 Th1 effector T cell response

STEMedicine ◽  
2020 ◽  
Vol 1 (4) ◽  
pp. e65 ◽  
Author(s):  
Haiying Zhang ◽  
Kun Han
Keyword(s):  
T Cells ◽  
Tumor Immunity ◽  
High Intensity ◽  
Th17 Cells ◽  
Focused Ultrasound ◽  
Transforming Growth Factor ◽  
Effector T Cells ◽  
T Cell Response ◽  
High Intensity Focused Ultrasound ◽  
Luciferase Assay

Background: Melanoma accounts for more than 80% of deaths from all dermatologic cancers, mainly due to its widespread metastasis. High intensity focused ultrasound (HIFU) is a promising technique for cancer therapy. Here, we investigated the efficacy of HIFU against melanoma and the underlying mechanisms. Methods: A melanoma allograft mouse model was established to examine the tumor progression and survival rate. Anti-tumor immunity was determined by measuring cytokines, regulatory T cells (Tregs), Th17 cells and CD8+ effector T cells. Western blot, qPCR, RNAi and luciferase assay were performed to confirm the expression and regulation of microRNA (miR)-9-5p and transforming growth factor beta (TGF-β). Results: HIFU exposure significantly suppressed melanoma growth and metastasis by activating interferon gamma (IFN-γ) secretion, inhibiting Tregs and Th17 cells, and stimulating CD8+ effector T cells. TGF-β was a direct target of miR-9-5p. The anti-tumor effect of HIFU might be mediated through the miR-9-5p/TGF-β pathway. Conclusion: HIFU activates anti-tumor response and alters tumor microenvironment, which may serve as a potential therapeutic strategy for melanoma treatment.

Immune response after high-intensity focused ultrasound ablation for H22 tumor

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 21169-21169 ◽  
Author(s):  
P. Zhou ◽  
M. Fu ◽  
J. Bai ◽  
Z. Wang ◽  
F. Wu
Keyword(s):  
Immune Response ◽  
Tumor Immunity ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Survival Rates ◽  
High Intensity Focused Ultrasound ◽  
Control Group ◽  
Term Survival ◽  
Hifu Ablation ◽  
Significant Difference

21169 Background: Previous results have shown that high intensity focused ultrasound (HIFU) ablation can potentially activate a host anti-tumor immunity. This study was to investigate whether acoustic cavitaion may enhance host immune responses after HIFU treatment for solid malignancy, and to explore the potential mechanisms regarding the enhanced anti-tumor immunity. Methods: (1) Tumor cell vaccine preparation: H22 cells were irradiated with HIFU (0.8MHz, 1050W/cm2, 90s); H22 cells were heated for one hour in 65°C water bath. (2) Animal study: 150 KM mice were randomly divided into three groups: control group, thermal group, and HIFU group. Each group had 50 mice for immune experiments. By using hypodermic injection, the mice in thermal group and HIFU group received either 0.2ml heat-treated H22 vaccine or 0.2ml HIFU-treated H22 vaccine in the left flank of each mouse. Those in control group received only injection with same amount of saline solution. The vaccination times were 4 sessions, once a week for 4 consecutive weeks. One week after last vaccination, each mouse was challenged with H22 tumor cells. All mice were followed up to observe the long-term survival in each group, and peripheral blood was collected to detect changes in T lymphocytes and their subsets by flow cytometry technique. Results: The tumor incidences and 6-week survival rates were observed 100% and 88% of mice in control group, 72.5% and 40% in thermal group, and 42.5% and 14% in HIFU group respectively. Compared to the values in either control group or thermal group, there was a significant decrease of tumor incidences and 6-week survival rates in HIFU group. The volume of tumor was obviously lower in HIFU group, and a significant difference was observed between HIFU group and thermal group or control group. Compared to the values in control group, there were a significant increase of CD4+ levels and CD4+/CD8+ ratio, and a significant decrease of CD8+ level in both HIFU group and thermal group. Conclusions: Antitumor immune response could be enhanced after HIFU ablation for H22 implanted tumor in mice, and acoustic cavitation could play an important role to stimulate host antitumor immune system. No significant financial relationships to disclose.

260: High Intensity Focused Ultrasound Combined with Endocrine Therapy in Treating High or Intermediate Risk Prostate Cancer

2006 ◽  
Vol 175 (4S) ◽  
pp. 86-86
Author(s):  
Makoto Sumitomo ◽  
Junichi Asakuma ◽  
Yasumasa Hanawa ◽  
Kazuhiko Nagakura ◽  
Masamichi Hayakawa
Keyword(s):  
Prostate Cancer ◽  
Endocrine Therapy ◽  
High Intensity ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Intermediate Risk ◽  
Risk Prostate Cancer

1400: Early Clinical Experience Using High-Intensity Focused Ultrasound for the Treatment of Renal Tumours

2005 ◽  
Vol 173 (4S) ◽  
pp. 379-380
Author(s):  
James E. Kennedy ◽  
Rowland O. Illing ◽  
Feng Wu ◽  
Gail R. ter Haar ◽  
Rachel R. Phillips ◽  
...  
Keyword(s):  
Clinical Experience ◽  
High Intensity ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Early Clinical Experience ◽  
Renal Tumours

Das Prostatakarzinom: aktuelle Diagnostik und Therapiestandard

Praxis ◽  
2016 ◽  
Vol 105 (16) ◽  
pp. 971-977
Author(s):  
Jan Brachlow ◽  
Martin Kälin ◽  
Marco Randazzo ◽  
Beat Förster ◽  
Hubert John
Keyword(s):  
High Intensity ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Psa Test ◽  
Eine Hohe ◽  
Psa Screening ◽  
Sekundäre Hormontherapie

Zusammenfassung. Das Prostatakarzinom zeigt eine hohe Prävalenz und ist daher für die behandelnden Ärzte medizinisch, aber auch gesundheitspolitisch relevant. PSA-Screening senkt die karzinomspezifische Mortalität, ist jedoch aufgrund der hohen Prävalenz mit einer Überdiagnostik verbunden. Dies fordert im Gegenzug einen verantwortungsbewussten Umgang mit dem PSA-Test («smarter screening»). Durch die robotergestützte Prostatektomie steht eine Therapie mit geringer Morbidität zur Behandlung des lokalisierten Prostatakarzinoms zur Verfügung. Das fokale Behandlungskonzept der HIFU (high-intensity focused ultrasound) ist vielversprechend, jedoch noch klinisch experimentell und sollte im Rahmen von Studien angeboten werden. Die Behandlungsmöglichkeiten beim metastasierten Prostatakarzinom wurden entscheidend vervielfältigt. Chemotherapie und die sekundäre Hormontherapie werden voraussichtlich vermehrt in früheren Phasen der Krankheit eine Rolle spielen, wodurch die Therapie für den einzelnen Patienten immer komplexer wird und individuell angepasst werden muss.

Sign in / Sign up

Export Citation Format

Share Document